Similarly, CHK1 inhibitor AZD7762 was reported to synergize with the DNA-damaging drug gemcitabine in reducing cell viability and suppressing tumor growth of LKB1 deficient lung cancer (Liu et al., 2017). This evidence concerns the gene STK11 and lung carcinoma.